Cell and Gene Outsourcing

  1. Why Clinical Operations Is The Bridge To Patient Access 8/6/2026

    Autologous cell therapies depend on time-critical supply chains. Automated processing, rapid testing, and centralized data help streamline vein-to-vein delivery and expand access.

  2. Integrated Vs. Modular CDMO Strategy For Advanced Therapies 8/6/2026

    Fragmented manufacturing increases tech transfer risk, delays timelines, and causes data loss. A unified framework preserves continuity and accelerates advanced therapy delivery.

  3. Scaling MSC Therapies To GMP: The Variability Challenge 8/6/2026

    Scaling stem cell therapies hinges on managing biological variability. Learn how automated 3D processing, defined media, and robust analytics drive predictable development.

  4. What Sponsors Value Most In CRO Partnerships 8/6/2026

    If your organization is uncertain about what truly separates strong research partnerships from disappointing ones, these data-driven findings can help you improve how you select, evaluate, and manage CRO partnerships.

  5. How Baby KJ Is Ushering In A New Era In CRISPR Medicine 8/5/2026

    A personalized gene-editing therapy was developed in months, showcasing how collaboration, manufacturing innovation, and regulatory alignment can accelerate treatments for rare diseases.

  6. Are Biopharma Companies Outsourcing Their Ability To Think? 8/5/2026

    Amid gaining immediate access to external manufacturing capabilities, sponsor companies can lose the foundational understanding required to govern that capability.

  7. Expand Trial Footprints Without Expanding Cryopreservation Risk 8/3/2026

    Transitioning from fresh to frozen starting material stabilizes cell therapy inputs, but isolated workflows introduce risk. Integrated logistics safeguard quality as trial footprints expand.

  8. When Local Variation Becomes Global Risk In Phase III 8/3/2026

    Late-stage therapy trials demand strict execution. Learn how local handling variations escalate into global risks and how early standardization safeguards therapeutic integrity and compliance.

  9. Regulatory Readiness Is Built Early 8/3/2026

    Building regulatory readiness early in cell and gene therapy development protects product integrity, prevents costly delays, and secures long-term program viability.

  10. How Sanofi Navigates Regulatory CMC Across Global Markets 8/3/2026

    Sanofi's Manda Pasarkar shares 20+ years of regulatory CMC expertise, covering FDA, EMA, and PMDA differences, CDMO partnerships, ICH guidelines, and AI's emerging role in global drug approvals.